**Executive Summary**
This document announces a Memorandum of Understanding (MoU) between the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, and Boehringer Ingelheim India Pvt. Ltd. to strengthen pharmaceutical education and research in India. It also unveils Cohort 2 of AMRITVA and extends grant support to five innovators under a CSR-backed program. The announcement was posted on February 21, 2026.
**Key Points / Main Content**
* **MoU Signing:**
* A Memorandum of Understanding (MoU) was signed between NIPER Raebareli and Boehringer Ingelheim India Pvt. Ltd.
* The MoU establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, academic exchange, and capability-building programmes.
* **AMRITVA Cohort 2 Launch:**
* Cohort 2 of AMRITVA (Alliance for Medicinal Research, Innovation, Translation & Value Acceleration) was launched.
* AMRITVA is implemented by SIIC, IIT Kanpur, in partnership with NIPER Raebareli and supported under CSR by Boehringer Ingelheim India Pvt. Ltd.
* **Grant Support:**
* Grant support has been extended to five innovators to facilitate the commercialization of their research.
* Financial assistance has been provided to three faculty-led projects and two research scholar-led projects.
* **Boehringer Ingelheim's Contribution:**
* Boehringer Ingelheim will provide access to its opnMe® open science platform to researchers and institutions.
* **Department of Pharmaceuticals' Role:**
* The Department of Pharmaceuticals supports the transition of the country's pharmaceutical sector from a volume-driven to a value-driven sector.
**Impact Analysis**
* **NIPER Raebareli, Faculty, Researchers and Students**
* **Impact:** Strengthened academic and research collaboration with Boehringer Ingelheim India, access to the opnMe® open science platform, and opportunities for capability-building programmes. Receipt of research grants.
* **Action Required:** Participate in collaborative activities, leverage access to opnMe® platform, and fulfill obligations related to grant support.
* **Boehringer Ingelheim India Pvt. Ltd.**
* **Impact:** Opportunity to collaborate with NIPER Raebareli, support research and innovation in the pharmaceutical sector as part of its CSR initiatives, and expand the reach of its opnMe® platform.
* **Action Required:** Provide access to the opnMe® platform and fulfill obligations under the MoU and CSR program.
* **Indian Pharmaceutical Sector**
* **Impact:** Supported in transitioning from a volume-driven to a value-driven sector through industry-academia partnerships and commercialization efforts.
* **Action Required:** Participate in policy interventions, infrastructure development, and incubation-led commercialization efforts.
Key Entities Referenced
National Institute of Pharmaceutical Education and Research (NIPER), Raebareli: Pharmaceutical education and research institute involved in a Memorandum of Understanding (MoU) with Boehringer Ingelheim India Pvt. Ltd. and partnering with SIIC, IIT Kanpur.
Boehringer Ingelheim India Pvt. Ltd.: Pharmaceutical company signing a Memorandum of Understanding (MoU) with NIPER Raebareli and providing Corporate Social Responsibility (CSR) support to AMRITVA initiative.
AMRITVA: Alliance for Medicinal Research, Innovation, Translation & Value Acceleration program that aims to strengthen India's innovation system and enable the translation of research outcomes.
Department of Pharmaceuticals: Ministry supporting the pharmaceutical sector's transition to a value-driven sector.
Memorandum of Understanding (MoU): Agreement between National Institute of Pharmaceutical Education and Research (NIPER), Raebareli and Boehringer Ingelheim India Pvt. Ltd. to advance pharmaceutical education and research.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
For Strengthening India’s Pharmaceutical
Ecosystem, NIPER-Boehringer MoU for
Education and Research & AMRITVA Cohort 2
Unveiled
Grant Support Extended to Five Innovators under CSR-
backed Programme
Posted On: 21 FEB 2026 3:58PM by PIB Delhi
To advance pharmaceutical education and research in India, a Memorandum of Understanding (MoU)
has been signed between National Institute of Pharmaceutical Education and Research (NIPER),
Raebareli and Boehringer Ingelheim India Pvt. Ltd. The MoU was signed in the presence of Shri
Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers in New
Delhi.
On the occasion, Cohort 2 of AMRITVA (Alliance for Medicinal Research, Innovation, Translation &
Value Acceleration) to strengthen India’s innovation system and enable translation of research outcomes
into viable pharmaceutical products and entrepreneurial ventures was also launched. AMRITVA is
implemented by the Startup Incubation and Innovation Centre (SIIC), IIT Kanpur, in partnership with the
National Institute of Pharmaceutical Education and Research (NIPER), Raebareli. This is an initiative
supported under Corporate Social Responsibility (CSR) by Boehringer Ingelheim India Pvt. Ltd.
In his address, Shri Manoj Joshi underscored the role of collaborative partnerships between academia
and industry in strengthening the research-to-market pipeline. He noted that such initiatives are critical
for advancing domestic innovation capabilities, encouraging entrepreneurship, and ensuring wider accessto cost-effective healthcare solutions.
Shri Awadhesh Kumar Choudhary, Senior Economic Advisor, Department of Pharmaceuticals; Ms.
Anugraha P, Director, Department of Pharmaceuticals; and Dr. Ashutosh Agnihotri, Chief Executive
Officer of SIIC, IIT Kanpur were present during the event.
As part of Cohort 2, five innovators have been selected for grant support aimed at facilitating the
commercialization of their research. Financial assistance has been provided to three faculty-led projects
and two research scholar-led projects.
The MoU signed between Boehringer Ingelheim India and NIPER Raebareli, including its Centre of
Excellence for Novel Drug Delivery Systems (CoE-NDDS), establishes a framework to strengthen
academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery
systems, academic exchange, and capability-building programmes.
As part of this collaboration, Boehringer Ingelheim will provide access to its opnMe® open science
platform to researchers and institutions, enabling scientific exchange and accelerating innovation in
healthcare.
The Department of Pharmaceuticals is supporting the country’s pharmaceutical sector to transition from a
volume-driven to a value-driven sector with focused policy interventions, infrastructure development,
strengthened industry-academia partnerships, and incubation-led commercialization efforts which are
aligned with the broader vision of Viksit Bharat 2047.
***
PC/PM
(Release ID: 2231194) Visitor Counter : 322
Read this release in: Urdu , ही